Catalog No.

KDC25201

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Cabiralizumab

Alternative Names

FPA-008, , CAS: 1613144-80-1

Background

Cabiralizumab (FPA008) is a humanized monoclonal antibody directed against colony stimulating factor-1 receptor (CSF1R), which is a member of the CSF1/PDGF receptor family of tyrosine-protein kinases. The developers of cabiralizumab including Apexigen, Bristol-Myers Squibb, Five Prime Therapeutics, University of Chicago and Yale University. Although it is reported to be designed for the treatment of tenosynovial giant cell tumor, the studies of treatment for pancreatic cancer, pigmented villonodular synovitis, malignant melanoma, non-small cell lung cancer, renal cell carcinoma and solid tumors also have been reported to be undergoing. The trails of pancreatic cancer and pigmented villonodular synovitis are in Phase II, while others are in Phase I. Orphan designation of cabiralizumab had been granted in the United States and European Commission for the treatment of pigmented villonodular synovitis.

Shipping

2-8 ℃

Note

For Research Use Only.

Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.

AntibodySystem由具有30多年蛋白抗体开发经验的 创立于法国,专注于生命科学和生物制药领域研究,***。AntibodySystem自主开发了高效、高产的真核重组表达系统,利用该系统生产了高质量的重组蛋白、抗体产品。目前产品包括药物靶点蛋白以及对照抗体药物、Invivo功能性抗体、SAA系列流式抗体、PEG抗体、磷酸化抗体、抗小分子抗体、ADA抗体、PK&ADA ELISA试剂盒。


佰乐博生物作为AntibodySystem在亚洲区授权 ,致力于为广大科研工作者提供 的产品服务。

如果您对我们的产品感兴趣,请联系027-65279366。

以上产品仅用于科研,产品信息以产品 为准